Leadership Transition at Newleos Therapeutics
Newleos Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for neuropsychiatric disorders, announced on October 21, 2025, that it has appointed Timothy Noyes as its new President and Chief Executive Officer. Noyes takes over from David Donabedian, Ph.D., the founding CEO of the company, who will remain involved in an advisory role. This leadership change marks a significant moment for Newleos as it continues to push forward with innovative treatment solutions for mental health conditions.
Noyes brings over 30 years of extensive experience in the biopharmaceutical sector, having successfully guided companies through crucial stages of development and expansion. He expressed enthusiasm about his new role, indicating that Newleos is at a critical juncture where its scientific advancements could significantly change treatment protocols for various anxiety-related disorders. He emphasized his eagerness to collaborate with the skilled team at Newleos, aiming to establish the company as a leader in neuropsychiatric treatment options for patients who have historically been underserved.
Noyes’ Impressive Track Record
Before joining Newleos, Noyes held the position of Chief Executive Officer at Aerovate Therapeutics, where he led the company through a successful initial public offering (IPO) and advanced its clinical programs for pulmonary arterial hypertension. His previous roles include serving as CEO of Proteon Therapeutics, where he oversaw the successful advancement of a biologic therapy through multiple clinical trial phases, and he has also played vital roles at GelTex Pharmaceuticals, where he was instrumental in launching a key treatment for end-stage renal disease.
Noyes’ academic credentials include a degree from Harvard College and an MBA from Harvard Business School, further underscoring his proficiency in leading complex biopharmaceutical organizations.
Future Directions for Newleos
In his new position, Noyes will be responsible for propelling Newleos’ pipeline of innovative treatments targeting mental health issues, including generalized anxiety disorder and substance use disorders. The company recently initiated clinical studies for its first-in-class GABAA-γ1 selective positive allosteric modulator and received clearance from the FDA for its V1a receptor antagonist, indicating strong momentum in its development efforts.
Christoph Westphal, M.D., Ph.D., Executive Chair of Newleos, acknowledged Noyes’s exceptional leadership capabilities and expressed confidence in his ability to steer the company through its next growth phase. He also commended Donabedian for his foundational contributions that helped secure critical clinical assets and establish a robust infrastructure for future success.
As Newleos Therapeutics embarks on this new chapter under Noyes’s leadership, the company remains committed to transforming the treatment landscape for those affected by serious psychiatric disorders, with an emphasis on innovative, effective solutions. For further details about Newleos and its ongoing projects, interested parties can visit their official website at www.newleos.com.
Related
